


**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2015**

Rs. In Lac.

	Particulars	CONSOLIDATED			
		Quarter Ended			Year Ended
		June-15	March-15	June-14	March-15
		(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
<b>1</b>	<b>PART- I</b>				
	<b>(a) Net Sales / Income from Operations</b>				
	Domestic	30,336	27,530	27,840	1,17,394
	Exports	28,696	23,265	21,773	89,379
	Total	59,032	50,795	49,613	2,06,773
	Less : Excise Duty	791	612	248	1,505
	Net Sales / Income from Operations	58,241	50,183	49,365	2,05,268
	<b>(b) Other Operating Income</b>	93	115	63	344
	<b>Total Income from Operations</b>	58,334	50,298	49,428	2,05,612
<b>2</b>	<b>Expenses</b>				
	(a) Decrease/(increase) in stock in trade and work in progress	(498)	447	(2,677)	(7,289)
	(b) Consumption of Raw Materials & Packing Materials	15,235	11,459	14,728	54,049
	(c) Purchase of traded goods	6,584	5,449	5,646	24,692
	(d) Employees' Cost	8,784	7,522	7,561	30,676
	(e) Marketing Expense	5,762	3,945	5,196	21,766
	(f) Research and Development Expense	4,795	3,049	2,953	12,162
	(g) Excise Duty	(14)	95	152	796
	(h) Other Expenditure	7,481	8,537	6,267	28,463
	<b>Total Expenses</b>	48,129	40,503	39,826	1,65,315
<b>3</b>	<b>Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	10,205	9,795	9,602	40,297
<b>4</b>	<b>Other Income</b>	3	185	18	230
<b>5</b>	<b>Profit from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	10,208	9,980	9,620	40,527
<b>6</b>	Depreciation	1,289	1,096	1,071	4,441
<b>7</b>	Interest (Net)	62	36	56	178
<b>8</b>	<b>Net Profit from Ordinary Activities before Tax</b>	8,857	8,848	8,493	35,908
<b>9</b>	<b>Tax Expense</b>				
	Less : Provision for Current Tax	1,875	1,831	1,735	7,635
	Add : MAT Credit Entitlement	572	739	-	739
	Less : Provision for Deferred Tax Liability	572	739	293	739
<b>10</b>	<b>Net Profit from Ordinary Activities after Tax</b>	6,982	7,017	6,465	28,273
<b>11</b>	Share of Profit of Associates	6	16	2	20
<b>12</b>	<b>Net Profit after Tax and share of profit of associates</b>	6,988	7,033	6,467	28,293
<b>13</b>	Paid up Equity Share Capital ( Face value of share ` 2/- )	3,770	3,770	3,770	3,770
<b>14</b>	Reserves excluding Revaluation Reserve	-	-	-	84,694
<b>15</b>	Basic & Diluted EPS (Not Annualised)	3.71	3.73	3.43	15.01
	<b>PART- II</b>				
<b>A</b>	<b>Particulars of Shareholding</b>				
<b>1</b>	<b>Public Shareholding</b>				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
<b>B</b>	<b>INVESTOR COMPLAINTS</b>				
	Pending at the beginning of the quarter				NIL
	Received during the quarter				NIL
	Disposed of during the quarter				NIL
	Remaining unresolved at the end of the quarter				NIL

Quarter Ended on 30th JUNE, 2015




**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th June, 2015**

Rs. in lacs

Particulars		STANDALONE			
		Quarter Ended			Year Ended
		June-15	March-15	June-14	March-15
<b>PART- I</b>		<b>(Reviewed)</b>	<b>(Reviewed)</b>	<b>(Reviewed)</b>	<b>(Audited)</b>
<b>1</b>	<b>(a) Net Sales / Income from Operations</b>				
	Domestic	30,336	27,530	27,840	1,17,394
	Exports	27,849	22,361	20,525	85,681
	Total	58,185	49,891	48,365	2,03,075
	Less : Excise Duty	791	612	248	1,505
	Net Sales / Income from Operations	57,394	49,279	48,117	2,01,570
	<b>(b) Other Operating Income</b>	92	101	63	330
	<b>Total Income from Operations</b>	<b>57,486</b>	<b>49,380</b>	<b>48,180</b>	<b>2,01,900</b>
<b>2</b>	<b>Expenses</b>				
	(a) Decrease/(Increase) in stock in trade and work in progress	(498)	447	(2,677)	(7,289)
	(b) Consumption of Raw Materials & Packing Materials	15,235	11,459	14,728	54,049
	(c) Purchase of traded goods	6,584	5,495	5,646	24,663
	(d) Employees' Cost	8,487	7,245	7,322	29,657
	(e) Marketing Expense	5,604	3,633	4,954	20,318
	(f) Research and Development Expense	4,023	2,820	2,754	10,903
	(g) Excise Duty	(14)	95	152	796
	(h) Other Expenditure	7,238	8,545	6,037	28,022
	<b>Total Expenses</b>	<b>46,659</b>	<b>39,739</b>	<b>38,916</b>	<b>1,61,119</b>
<b>3</b>	<b>Profit from Operations before Other Income, Interest, Depreciation &amp; Exceptional Items</b>	<b>10,827</b>	<b>9,641</b>	<b>9,264</b>	<b>40,781</b>
<b>4</b>	<b>Other Income</b>	<b>3</b>	<b>12</b>	<b>18</b>	<b>57</b>
<b>5</b>	<b>Profit/(Loss) from Ordinary Activities before Interest, Depreciation, &amp; Exceptional Items</b>	<b>10,830</b>	<b>9,653</b>	<b>9,282</b>	<b>40,838</b>
<b>6</b>	Depreciation	1,288	1,096	1,071	4,441
<b>7</b>	Interest (Net)	37	5	56	111
<b>8</b>	<b>Net Profit from Ordinary Activities before Tax</b>	<b>9,505</b>	<b>8,552</b>	<b>8,155</b>	<b>36,286</b>
<b>9</b>	<b>Tax Expense</b>				
	Less : Provision for Current Tax	1,875	1,843	1,714	7,625
	Add : MAT Credit Entitlement	572	739	-	739
	Less : Provision for Deferred Tax Liability	572	739	293	739
<b>10</b>	<b>Net Profit from Ordinary Activities after Tax</b>	<b>7,630</b>	<b>6,709</b>	<b>6,148</b>	<b>28,661</b>
<b>11</b>	Paid up Equity Share Capital ( Face value of share Rs. 2/- )	3,770	3,770	3,770	3,770
<b>12</b>	Reserves excluding Revaluation Reserve	-	-	-	79,586
<b>13</b>	Basic & Diluted EPS (Not Annualised)	4.05	3.56	3.26	15.20
<b>PART- II</b>					
<b>A</b>	<b>Particulars of Shareholding</b>				
<b>1</b>	<b>Public Shareholding</b>				
	- Number of Shares	48777294	48777294	48777294	48777294
	- Percentage of Shareholding	25.87	25.87	25.87	25.87
<b>2</b>	<b>Promoters and Promoter Group Shareholding</b>				
	- Fully Non - Encumbered				
	- Number of Shares	139738620	139738620	139738620	139738620
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of Shares (as a % of the total share capital of the Company)	74.13	74.13	74.13	74.13
<b>B</b>	<b>INVESTOR COMPLAINTS</b>				
	Pending at the beginning of the quarter				NIL
	Received during the quarter				NIL
	Disposed of during the quarter				NIL
	Remaining unresolved at the end of the quarter				NIL

Quarter Ended on 30th June, 2015



**Notes :**

- 1 The above results, have been duly reviewed by Statutory Auditors, recommended by the Audit Committee and approved by the Board of Directors.
- 2 The Company has opted to publish consolidated financial results, pursuant to option made available as per clause 41 of the listing Agreement. The Standalone Financial Results are available on the company's website [www.alembic-india.com](http://www.alembic-india.com).

The key information on the standalone financial results are as under:

Rs in Lacs


Particulars	Quarter Ended			Year Ended
	Jun-15	Mar-15	Jun-14	Mar-15
	(Reviewed)	(Reviewed)	(Reviewed)	(Audited)
Net Sales / Income from Operations	57,486	49,380	48,180	2,01,900
Profit Before Tax	9,505	8,552	8,155	36,286
Profit After Tax	7,630	6,709	6,148	28,661

- 3 The Company is engaged in Pharmaceuticals business only and therefore, there is only one reportable segment in accordance with the Accounting Standard on Segment Reporting (AS-17).
- 4 The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara


Date : 31st July, 2015

For Alembic Pharmaceuticals Limited



Chirayu Amin

Chairman and Managing Director



Visit us at [www.alembic-india.com](http://www.alembic-india.com)

# F-7 Laxmi Mills  
Shakti Mills Lane (Off Dr E Moses Rd)  
Mahalaxmi Mumbai 400 011 India .  
Tel : 91 22 2493 2502 / 6655 1770  
Fax : 91 22 6655 1774  
Grams : VERIFY  
www.KSAiyar.com  
Mail@KSAiyar.com

To,  
The Board of Directors;  
**Alembic Pharmaceuticals Limited;**  
Alembic Road,  
Vadodara, 390 003

RE: **LIMITED REVIEW OF THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2015 PREPARED BY THE COMPANY.**

**1. INTRODUCTION**

We have reviewed the accompanying statement of unaudited consolidated financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on 30<sup>th</sup> June, 2015 except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.

**2. SCOPE OF REVIEW**

- 2.1 We conducted our review in accordance with Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 2.2 We report that the unaudited consolidated financial results have been prepared by the Company's management in accordance with the requirements of Accounting Standard 21 – Consolidated Financial Statements and Accounting Standard 23 - Accounting for Investments in Associates in Consolidated Financial Statements and Accounting Standard 27 – Financial Reporting of Interests in Joint Ventures, notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 on the basis of the separate unaudited

financial results of its (a) 100% Subsidiary i.e. Alembic Global Holding SA, Switzerland (standalone) (b) 6 Subsidiaries, a Joint Venture (which is yet to start any operational activities) and an Associate of Alembic Global Holding SA, Switzerland, and (c) An Associate of the Company. These unaudited standalone financial results have not been reviewed by us or any other Auditors and are as submitted to us by the Company's management.


The unaudited consolidated financial results of Company include

- (a) Company's share (i) in the consolidated Revenue of the Subsidiary of Rs. 4267.56 Lacs for the quarter ended on 30<sup>th</sup> June, 2015 (ii) in consolidated loss of the Subsidiary of Rs. 646.05 Lakhs for the quarter ended on 30<sup>th</sup> June, 2015 and (iii) in the consolidated net assets of the Subsidiary of Rs. 7284.67 Lacs as at the quarter ended on 30<sup>th</sup> June, 2015.
- (b) Company's share in the net profit (after tax) of its Associate of Rs. 3.33 Lacs for the quarter ended on 30<sup>th</sup> June, 2015.

**3. CONCLUSION**

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 and other recognised accounting practices and policies has not disclosed the Information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.  
Chartered Accountants  
FRN: 100186W

  
Rajesh S. Joshi  
Partner  
M.No. 38526

Place: Vadodara  
Date: 31<sup>st</sup> July, 2015

# K. S. AIYAR & CO

CHARTERED ACCOUNTANTS

# F-7 Laxmi Mills  
Shakti Mills Lane (Off Dr E Moses Rd)  
Mahalaxmi Mumbai 400 011 India.  
Tel : 91 22 2493 2502 / 6655 1770  
Fax : 91 22 6655 1774  
Grams : VERIFY  
www.KSAiyar.com  
Mail@KSAiyar.com

To,  
The Board of Directors;  
**Alembic Pharmaceuticals Limited;**  
Alembic Road,  
Vadodara 390 003.

RE: **LIMITED REVIEW OF THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>th</sup> JUNE, 2015 PREPARED BY THE COMPANY.**

## 1. INTRODUCTION

We have reviewed the accompanying statement of unaudited **standalone** financial results of **Alembic Pharmaceuticals Limited** for the quarter ended on **30<sup>th</sup> June, 2015** except for the disclosures regarding public shareholding and Promoter and Promoter Group shareholding which have been traced from disclosures made by the management, but have neither been reviewed nor been audited by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Management is responsible for the preparation and fair presentation of this interim financial information in accordance with Indian Generally Accepted Accounting Principles. Our responsibility is to issue a report on this Statement based on our review.


## 2. SCOPE OF REVIEW

We conducted our review in accordance with Standard on Review Engagements (**SRE**) **2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity"** issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether this Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

## 3. CONCLUSION

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards notified under section 133 of the Companies Act 2013 read with Rule 7 of the Companies (Accounts) Rules 2014 and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.S.Aiyar & Co.  
Chartered Accountants  
FRN: 100186W

  
Rejesh S. Joshi  
Partner  
M.No. 38526

Place: Vadodara  
Date: 31<sup>st</sup> July, 2015

Offices also at  
Chennai Kolkata Goa  
Bangalore Coimbatore



**For Immediate Release**

**Net Revenues up 19%, Net Profit up 8%**

Vadodara, 31<sup>st</sup> July, 2015

Alembic Pharmaceuticals Limited reported its performance for the first quarter ending 30<sup>th</sup> June 2015. The consolidated results were taken on record by the board of directors at a meeting held in Vadodara today.

**Financial Highlights**

- Net Sales up 19% to Rs 590 Crore
- Net Profit up 8% to Rs 70 crore
- India Branded Formulation up 18% to Rs. 263 crore
- International Generics up 47% for the quarter to Rs. 168 Crore

**Commenting on the results, Mr. Shaunak Amin, Joint Managing Director, Alembic Pharmaceuticals Limited said** "We have seen exceptional growth in the topline on all the businesses, we however have also accelerated our R&D program, which led to an expense increase of 62% which has impacted our margins"

**Operational Highlights**

**India Branded Formulations Business**

- The India Branded formulations business grew by 18% to Rs 263 crores in the quarter against Rs 223 crores
- Specialty Segment grew by 22% and Acute Segment grew by 12%
- Alembic's "Tellzy" is the fastest growing Telmisartan brand, 50% as per ORG MAT May 2015, and is now the 3<sup>rd</sup> ranked brand in the Telmisartan market.

CIN:  
Page: 1 of 3  
L24230GJ2010PLC061123

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2282506  
Website : [www.alembic-india.com](http://www.alembic-india.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in)

### International Generics

- Successful Launch of Aripiprazole Generic on Day 1
- International Generics grew by 47% to Rs 168 crores in the quarter.
- During the quarter 8 ANDA approvals were received.
- 1 DMF application was filed during the quarter, taking cumulative DMF filings of the Company to 73.
- Successfully audited by the USFDA at API Karkhadi Plant

Summary of Total Revenue is as under:

Particulars	(Rs in Lacs)		
	Q1 FY16	Q1 FY15	% Change
<b>Formulation</b>			
India Branded	26275	22328	18%
India Generics	2859	2522	13%
International Branded	836	2268	(-)63%
International Generics	16768	11381	47%
<b>API</b>	11683	10631	10%
<b>Export Incentives</b>	611	483	
<b>Total</b>	<b>59032</b>	<b>49613</b>	<b>19%</b>

The Profit break-up is as under:

Particulars	(Rs in Lacs)		
	Q1 FY16	Q1 FY15	% Change
EBITDA	10205	9602	6%
Profit Before Tax	8857	8493	4%
Net Profit after Tax	6988	6467	8%

CIN: 272002  
Page: 2 of 3  
L24230GJ2010PLC061123

### ALEMBIC PHARMACEUTICALS LIMITED





About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities all over the world including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at [www.alembic-india.com](http://www.alembic-india.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information contact:**

<b>Ajay Kumar Desai</b> <b>Phone: +91 22 – 306 11681</b> <b>Email: <a href="mailto:ajay.desai@alembic.co.in">ajay.desai@alembic.co.in</a></b>	<b>Mitanshu Shah</b> <b>Phone: +91 265 – 3007630</b> <b>Email: <a href="mailto:mitanshu.shah@alembic.co.in">mitanshu.shah@alembic.co.in</a></b>
---	---

**ALEMBIC PHARMACEUTICALS LIMITED**